Pharmacokinetics of Darunavir/Ritonavir in Asian HIV-1-Infected Children Aged ≥7 Years

Chokephaibulkit, Kulkanya; Prasitsuebsai, Wasana; Wittawatmongkol, Orasri; Gorowara, Meena; Phongsamart, Wanatpreeya; Sophonphan, Jiratchiya; Kerr, Stephen J.; Vanprapar, Nirun; Puthanakit, Thanyawee; Pasomsap, Chayapa; Sekar, Vanitha; Burger, David M.; Ananworanich, Jintanat

doi:10.3851/imp2347

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acyclovir [43] Preterm and term infants Population Yes Darunavir/ritonavir [44] Children Non-compartmental…”

Section: Population Yesmentioning

confidence: 99%

Advances in Pediatric Pharmacology, Therapeutics, and Toxicology

Paul

2010

Advances in Pediatrics

View full text Add to dashboard Cite

Significant advancements have been made in pediatric therapeutics and pharmacology over the last two years. In the United States, passage of the Food and Drug Administration Safety and Innovation Act has made the Best Pharmaceuticals for Children Act and Pediatric Research Equity Act permanent, and ensured that studies will be conducted in neonates. In Europe, the Pediatric Regulation, which went into effect in early 2007, has also provided a framework encouraging an expansion of pediatric research. Because of such regulatory involvement, a greater number of studies are being performed, and more pediatric dosing, efficacy, and safety information is being incorporated into product labels. The goal of this publication is to highlight important advancements made in the field of pediatric pharmacology, toxicology, and therapeutics from

show abstract

“…Acyclovir [43] Preterm and term infants Population Yes Darunavir/ritonavir [44] Children Non-compartmental…”

Section: Population Yesmentioning

confidence: 99%